Predictive Biotech’s mission is to convert cutting edge research in human biology into effective human cell and tissue products for regenerative medicine. By working hand in hand with researchers from across the globe we are on a pathway to help rethink and reshape the future of regenerative medicine.
Provide the highest quality human cell and tissue products (HCT/P) to our physician customers and their patients.
Advances in the procurement and processing of human cell and tissue will allow Predictive Biotech to establish a strong pipeline of revolutionary Human Cell and Tissue Products (HCT/P) for regenerative medicine applications.
Predictive Biotech is a wholly owned subsidiary of Predictive Technology Group, Inc. (PRED). Predictive Technology Groups’s core focus is to revolutionize the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease’s onset and progression. PRED uses this information as the cornerstone in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.
For more information please contact investor relations at 757-306-6090.
OUR COMMITMENT TO HELP OUR CLIENTS RECEIVE THE CUTTING EDGE IN REGENERATIVE MEDICINE IS OUR PRIORITY
Predictive biotech is in the business of developing cutting edge advancements in human cell and tissue products. The data we collect in collaboration with other research institutes and our clients are the cornerstone in our product development.